| P50 | author | Elena Generali | Q57080635 |
| | Carlo Selmi | Q42356913 |
| P2093 | author name string | Piersandro Riboldi | |
| | Marco Folci | |
| P2860 | cites work | 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. | Q54164380 |
| | The heart and cardiac conduction system in polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients. | Q54386455 |
| | Cardiovascular manifestations of mixed connective tissue disease in adults. | Q54486567 |
| | Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study | Q58109394 |
| | Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure | Q26823443 |
| | Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies | Q26864958 |
| | Libman-Sacks Endocarditis: Detection, Characterization, and Clinical Correlates by Three-Dimensional Transesophageal Echocardiography. | Q27311646 |
| | Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA) | Q28243715 |
| | International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 |
| | Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 |
| | Role of cardiovascular magnetic resonance imaging (CMR) in the diagnosis of acute and chronic myocarditis | Q30573820 |
| | The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). | Q33173262 |
| | Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 |
| | Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution | Q33375735 |
| | The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe | Q33385759 |
| | Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome | Q33495531 |
| | EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 |
| | Cardiac manifestations in primary Sjögren's syndrome | Q33579062 |
| | Cardiac arrhythmias and conduction defects in systemic sclerosis | Q33783945 |
| | Systemic sclerosis and the heart: current diagnosis and management | Q34012584 |
| | Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. | Q34126026 |
| | Cardiac manifestations in systemic sclerosis | Q34251904 |
| | Myocarditis of mixed connective tissue disease: favourable outcome after intravenous pulsed cyclophosphamide | Q48256482 |
| | Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography | Q48333798 |
| | Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. | Q51126183 |
| | Successful steroid therapy for heart failure due to myocarditis associated with primary biliary cirrhosis. | Q53173511 |
| | Inverse relation of total serum bilirubin to coronary artery calcification score detected by multidetector computed tomography in males. | Q53179507 |
| | Proinflammatory HLA-DRB1*01-haplotype predisposes to ST-elevation myocardial infarction. | Q53669495 |
| | Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 |
| | Predicting prognosis in stable angina--results from the Euro heart survey of stable angina: prospective observational study | Q34334496 |
| | Polymyositis and dermatomyositis | Q34542218 |
| | Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment | Q34563216 |
| | Myocarditis in systemic lupus erythematosus | Q34980901 |
| | Cardiac involvement in systemic autoimmune diseases | Q34981326 |
| | Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions | Q35121150 |
| | Autoantibody-mediated atherosclerosis | Q35172086 |
| | EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic | Q35177998 |
| | THE CARDIOVASCULAR MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. | Q35456791 |
| | Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome | Q35554870 |
| | The influence of rheumatoid arthritis disease characteristics on heart failure. | Q35915244 |
| | Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. | Q36031031 |
| | Imaging of cardiovascular complications in patients with systemic lupus erythematosus. | Q36052795 |
| | Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. | Q36085051 |
| | Neonatal lupus: basic research and clinical perspectives. | Q36142480 |
| | Treatment of mixed connective tissue disease | Q36220500 |
| | Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus | Q36220831 |
| | Nonorgan specific autoantibodies and heart damage | Q36283415 |
| | Cardiac imaging techniques in systemic autoimmune diseases | Q36283477 |
| | Cardiomyopathy related to antimalarial therapy with illustrative case report | Q36521126 |
| | Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies | Q36570988 |
| | Cardiotoxicity of antimalarial drugs | Q36889570 |
| | The role of antiphospholipid syndrome in cardiovascular disease | Q37061156 |
| | Valvular and coronary heart disease in systemic inflammatory diseases: Systemic Disorders in heart disease | Q37215996 |
| | Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients | Q37404896 |
| | Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases | Q37438934 |
| | Cardiac pathology of systemic lupus erythematosus. | Q37533906 |
| | Brief report: rheumatoid arthritis is associated with left ventricular concentric remodeling: results of a population-based cross-sectional study. | Q37555936 |
| | Geoepidemiology of systemic sclerosis | Q37631192 |
| | Cardiological features in idiopathic inflammatory myopathies. | Q37772062 |
| | Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin | Q37782589 |
| | Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review | Q37786411 |
| | Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review | Q37996153 |
| | Assessing the safety of biologic agents in patients with rheumatoid arthritis | Q38020463 |
| | The autoimmune side of heart and lung diseases | Q38051261 |
| | Is it safe to use TNF-α blockers for systemic inflammatory disease in patients with heart failure? Importance of dosage and receptor specificity | Q38067917 |
| | Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure | Q38075673 |
| | Cardiovascular disease in autoimmune rheumatic diseases. | Q38094402 |
| | The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review | Q38121867 |
| | Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity | Q38161572 |
| | The heart in inflammatory myopathies | Q38165455 |
| | Cardiac manifestations of systemic lupus erythematosus | Q38165458 |
| | Cardiac involvement in mixed connective tissue disease: a systematic review | Q38179108 |
| | Cardiac and muscular involvement in idiopathic inflammatory myopathies: noninvasive diagnostic assessment and the role of cardiovascular and skeletal magnetic resonance imaging. | Q38215086 |
| | Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature | Q38245569 |
| | Antiphospholipid syndrome and the heart: a case series and literature review | Q38280840 |
| | Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. | Q38283188 |
| | The clinical spectrum of autoimmune congenital heart block | Q38387739 |
| | Epigenetics and Systemic Lupus Erythematosus: Unmet Needs | Q38553346 |
| | Cardiovascular comorbidity in rheumatic diseases | Q38568465 |
| | The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. | Q38619523 |
| | Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging | Q38652145 |
| | Autoimmune congenital heart block: complex and unusual situations | Q38695221 |
| | Cardiovascular manifestations of systemic lupus erythematosus: current perspective | Q39367850 |
| | Myocarditis in mixed connective tissue disease: clinical and pathologic study of three cases and review of the literature | Q39478678 |
| | The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature | Q39614635 |
| | A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study | Q40230825 |
| | Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival | Q41189863 |
| | Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment | Q41587455 |
| | Direct inhibition of expressed cardiac l- and t-type calcium channels by igg from mothers whose children have congenital heart block | Q43546662 |
| | Clinical course, prognosis, and causes of death in mixed connective tissue disease | Q43572904 |
| | Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). | Q43586296 |
| | Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease | Q43788592 |
| | Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. | Q44068950 |
| | Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome | Q44183283 |
| | Left ventricular diastolic dysfunction -- early cardiac impairment in patients with polymyositis/dermatomyositis: a tissue Doppler imaging study | Q44460497 |
| | The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients | Q44593960 |
| | Immunoglobulin M Type of Autoantibodies to Oxidized Low-Density Lipoprotein Has an Inverse Relation to Carotid Artery Atherosclerosis | Q44608860 |
| | Pericardial fluid profiles of pericardial effusion in systemic sclerosis patients | Q44821122 |
| | Cholesterol pericarditis associated with rheumatoid arthritis: a rare cause of pericardial effusion | Q45843421 |
| | Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. | Q46015999 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 145-171 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Advances in Experimental Medicine and Biology | Q4686385 |
| P1476 | title | Immune-Mediated Heart Disease | |
| P478 | volume | 1003 | |